Provectus Pharmaceuticals Receives Patent Allowances In Europe And China

Main Category: Pharma Industry / Biotech Industry
Also Included In: MRI / PET / Ultrasound
Article Date: 28 Feb 2008 - 2:00 PDT

email to a friend   printer friendly   opinions  

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent applications in Europe and China covering diagnostic use of PV-10 and a number of related agents in CT and MRI imaging. The pending patents cover products for diagnosis of cancer and other serious diseases.

"These cases augment our international portfolio of twenty-six issued patents and four pending patents, along with our U.S. patent portfolio of sixteen issued and five pending patents," said Craig Dees, PhD, CEO of Provectus Pharmaceuticals. "As important milestones, they demonstrate the scope of our patent activity that spans markets ranging from the developed world to the rapidly developing world."

About Provectus

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, http://www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at http://www.pvct.com or contact the Investor Relations Group via the information provided below.

Forward-Looking Statements

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Provectus Pharmaceuticals

• Additional
• References
• Citations